Concepedia

Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study

Zev A. Wainberg, Peter C. Enzinger, Yoon‐Koo Kang, Shukui Qin, Kensei Yamaguchi, Inho Kim, Anwaar Saeed, Sang Cheul Oh, Jin Li, Hacı Mehmet Türk,

The Lancet Oncology · 2022 · 222 citations · 18 references

DOI

Concepts

References

18

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Hyuna Sung, Jacques Ferlay, Rebecca L. Siegel et al. · CA A Cancer Journal for Clinicians · 2021 · 112.5K citations · Full text

, , +16

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram et al. · CA A Cancer Journal for Clinicians · 2018 · 87.7K citations · Full text

, , +16

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian, Kohei Shitara, Markus Moehler et al. · The Lancet · 2021 · 2.9K citations · Full text

, , +16

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

Ghassan K. Abou‐Alfa, Vaibhav Sahai, Antoine Hollebecque et al. · The Lancet Oncology · 2020 · 1.6K citations · Full text

, , +11

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

Yohann Loriot, Andrea Necchi, Se Hoon Park et al. · New England Journal of Medicine · 2019 · 1.4K citations · Full text

, , +15